# RFX6

## Overview
RFX6 is a gene that encodes the regulatory factor X6, a winged-helix transcription factor crucial for the development and function of pancreatic beta cells, which are responsible for insulin secretion. The RFX6 protein plays a significant role in the transcriptional regulation of genes necessary for beta cell differentiation and function, including those involved in calcium homeostasis and insulin exocytosis. It is highly expressed in adult human pancreatic islets and is essential for maintaining proper insulin gene transcription and secretion. Mutations in the RFX6 gene are linked to various clinical conditions, including Mitchell-Riley syndrome and certain forms of diabetes, due to impaired beta cell function (Chandra2014RFX6; Ibrahim2024RFX6; Passone2022Mitchell–Riley).

## Structure


## Function
The RFX6 gene encodes a winged-helix transcription factor that plays a crucial role in the development and function of pancreatic beta cells, which are responsible for insulin secretion. In healthy human cells, RFX6 is involved in the transcriptional regulation of genes necessary for beta cell differentiation and function, including those encoding voltage-gated calcium channels essential for insulin exocytosis (Chandra2014RFX6; Ibrahim2024RFX6). RFX6 modulates calcium homeostasis by influencing the expression of L-type calcium channels, which are critical for glucose-stimulated insulin secretion (Chandra2014RFX6).

RFX6 is highly expressed in adult human pancreatic islets and is essential for maintaining proper insulin gene transcription and secretion. Knockdown studies have shown that reduced RFX6 expression leads to decreased insulin mRNA levels and impaired glucose-stimulated insulin secretion, highlighting its importance in beta cell function (Chandra2014RFX6). Additionally, RFX6 is involved in the differentiation of pancreatic endocrine cells, regulating genes necessary for pancreatic development and maintaining the pancreatic progenitor pool (Ibrahim2024RFX6). Its dysfunction can predispose individuals to diabetes due to impaired beta cell function (Ibrahim2024RFX6).

## Clinical Significance
Mutations in the RFX6 gene are associated with several significant clinical conditions. Biallelic mutations in RFX6 cause Mitchell-Riley syndrome, a rare genetic disorder characterized by neonatal diabetes, pancreatic hypoplasia, gallbladder agenesis or hypoplasia, duodenal atresia, and severe chronic diarrhea. This syndrome results from the impaired development and function of insulin-secreting pancreatic beta-cells due to the loss of RFX6 function (Spiegel2011Clinical; Passone2022Mitchell–Riley). 

Heterozygous protein truncating variants (PTVs) in RFX6 are linked to maturity-onset diabetes of the young (MODY) with reduced penetrance. These variants are more prevalent in certain populations, such as the Finnish, and are associated with beta-cell dysfunction, leading to diabetes (Patel2017Heterozygous). 

RFX6 haploinsufficiency, due to heterozygous mutations, predisposes individuals to various forms of diabetes, including type 2 and gestational diabetes, by impairing beta-cell function and insulin secretion (Ibrahim2024RFX6). These mutations can also lead to a syndromic form of neonatal diabetes, as seen in Mitchell-Riley syndrome, with severe developmental issues (Sansbury2015Biallelic).

## Interactions
RFX6 is a transcription factor that participates in various interactions with proteins and nucleic acids, influencing several biological processes. In hepatocellular carcinoma (HCC), RFX6 interacts with DTX2, a regulator of the Notch signaling pathway, by targeting NOTCH1 and stabilizing its transcription. This interaction is significant in the progression of HCC, as it affects cancer cell proliferation, migration, and invasion (Song2021Inhibition). RFX6 is also involved in the regulation of immune responses, particularly affecting T cell activity in HCC (Song2021Inhibition).

In the context of pancreatic development, RFX6 binds directly to several transcription factors, including Pdx1, Neurod1, Hnf1a, Nkx6-1, St18, and Shox2, which are crucial for pancreatic development and insulin translation (Cheng2019Identification). This binding suggests that RFX6 plays a role in regulating gene promoters and distal enhancers, influencing the expression of genes involved in these processes (Cheng2019Identification).

In prostate cancer, RFX6 is implicated in promoting metastasis and drug resistance by upregulating the transcription factor HOXA10, which is linked to adverse outcomes. RFX6 facilitates the epithelial-mesenchymal transition (EMT) process and modulates the TGFβ/SMAD signaling axis, contributing to cancer progression (Zhong2024RFX6).


## References


1. (Zhong2024RFX6) RFX6 at locus 6q22 confers metastasis and drug resistance in prostate cancer. This article has 0 citations.

[2. (Chandra2014RFX6) Vikash Chandra, Olivier Albagli-Curiel, Benoit Hastoy, Julie Piccand, Clotilde Randriamampita, Emmanuel Vaillant, Hélène Cavé, Kanetee Busiah, Philippe Froguel, Martine Vaxillaire, Patrik Rorsman, Michel Polak, and Raphael Scharfmann. Rfx6 regulates insulin secretion by modulating ca2+ homeostasis in human β cells. Cell Reports, 9(6):2206–2218, December 2014. URL: http://dx.doi.org/10.1016/j.celrep.2014.11.010, doi:10.1016/j.celrep.2014.11.010. This article has 79 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1016/j.celrep.2014.11.010)

[3. (Spiegel2011Clinical) Ronen Spiegel, Angus Dobbie, Corina Hartman, Liat de Vries, Sian Ellard, and Stavit A. Shalev. Clinical characterization of a newly described neonatal diabetes syndrome caused by rfx6 mutations. American Journal of Medical Genetics Part A, 155(11):2821–2825, September 2011. URL: http://dx.doi.org/10.1002/ajmg.a.34251, doi:10.1002/ajmg.a.34251. This article has 38 citations.](https://doi.org/10.1002/ajmg.a.34251)

[4. (Patel2017Heterozygous) Kashyap A. Patel, Jarno Kettunen, Markku Laakso, Alena Stančáková, Thomas W. Laver, Kevin Colclough, Matthew B. Johnson, Marc Abramowicz, Leif Groop, Päivi J. Miettinen, Maggie H. Shepherd, Sarah E. Flanagan, Sian Ellard, Nobuya Inagaki, Andrew T. Hattersley, Tiinamaija Tuomi, Miriam Cnop, and Michael N. Weedon. Heterozygous rfx6 protein truncating variants are associated with mody with reduced penetrance. Nature Communications, October 2017. URL: http://dx.doi.org/10.1038/s41467-017-00895-9, doi:10.1038/s41467-017-00895-9. This article has 102 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-017-00895-9)

[5. (Sansbury2015Biallelic) Francis H Sansbury, Birgül Kirel, Richard Caswell, Hana Lango Allen, Sarah E Flanagan, Andrew T Hattersley, Sian Ellard, and Charles J Shaw-Smith. Biallelic rfx6 mutations can cause childhood as well as neonatal onset diabetes mellitus. European Journal of Human Genetics, 23(12):1744–1748, August 2015. URL: http://dx.doi.org/10.1038/ejhg.2015.161, doi:10.1038/ejhg.2015.161. This article has 33 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/ejhg.2015.161)

[6. (Passone2022Mitchell–Riley) Caroline de Gouveia Buff Passone, Gaëlle Vermillac, Willem Staels, Alix Besancon, Dulanjalee Kariyawasam, Cécile Godot, Cécile Lambe, Cécile Talbotec, Muriel Girard, Christophe Chardot, Laureline Berteloot, Taymme Hachem, Alexandre Lapillonne, Amélie Poidvin, Caroline Storey, Mathieu Neve, Cosmina Stan, Emmanuelle Dugelay, Anne-Laure Fauret-Amsellem, Yline Capri, Hélène Cavé, Marina Ybarra, Vikash Chandra, Raphaël Scharfmann, Elise Bismuth, Michel Polak, Jean Claude Carel, Bénédicte Pigneur, and Jacques Beltrand. Mitchell–riley syndrome: improving clinical outcomes and searching for functional impact of rfx-6 mutations. Frontiers in Endocrinology, June 2022. URL: http://dx.doi.org/10.3389/fendo.2022.802351, doi:10.3389/fendo.2022.802351. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fendo.2022.802351)

[7. (Cheng2019Identification) Cheng Cheng, Jing Lu, Xi Cao, Fang-yuan Yang, Jing-yi Liu, Li-ni Song, Han Shen, Chang Liu, Xiao-rong Zhu, Jian-bo Zhou, and Jin-kui Yang. Identification of rfx6 target genes involved in pancreas development and insulin translation by chip-seq. Biochemical and Biophysical Research Communications, 508(2):556–562, January 2019. URL: http://dx.doi.org/10.1016/j.bbrc.2018.11.133, doi:10.1016/j.bbrc.2018.11.133. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2018.11.133)

[8. (Ibrahim2024RFX6) Hazem Ibrahim, Diego Balboa, Jonna Saarimäki-Vire, Hossam Montaser, Oleg Dyachok, Per-Eric Lund, Muhmmad Omar-Hmeadi, Jouni Kvist, Om P. Dwivedi, Väinö Lithovius, Tom Barsby, Vikash Chandra, Solja Eurola, Jarkko Ustinov, Tiinamaija Tuomi, Päivi J. Miettinen, Sebastian Barg, Anders Tengholm, and Timo Otonkoski. Rfx6 haploinsufficiency predisposes to diabetes through impaired beta cell function. Diabetologia, 67(8):1642–1662, May 2024. URL: http://dx.doi.org/10.1007/s00125-024-06163-y, doi:10.1007/s00125-024-06163-y. This article has 2 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1007/s00125-024-06163-y)

[9. (Song2021Inhibition) Mu Song, Mulati Kuerban, Lu Zhao, Xiaolin Peng, and Youqin Xu. Inhibition of rfx6 suppresses the invasive ability of tumor cells through the notch pathway and affects tumor immunity in hepatocellular carcinoma. Frontiers in Oncology, December 2021. URL: http://dx.doi.org/10.3389/fonc.2021.801222, doi:10.3389/fonc.2021.801222. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.801222)